Vancouver, BC, November 27, 2023--Algernon Pharmaceuticals Inc., a Canadian clinical stage pharmaceutical development company, announced that it has signed a Letter of Intent ("LOI") with Seyltx Inc., a privately owned U.S. based drug development company, to acquire Algernon's NP-120 ("Ifenprodil") research program for USD $2M cash and a 20% common share equity position in Seyltx.

Vancouver, BC, November 20, 2023--Algernon Pharmaceuticals Inc. a clinical stage pharmaceutical development company announced that it has received a Notice of Allowance from the Japanese Patent Office for patent application No. 2021-512244 entitled "Compositions and Methods for Treating Non-Alcoholic Steatohepatitis" with NP-251 (Repirinast).

Vancouver, BC, September 11, 2023--Algernon Pharmaceuticals Inc., a clinical stage pharmaceutical development company, announced that it has been issued a patent from the United States Patent and Trademark Office (USPTO), No. 11744808, for its lead chronic kidney Disease (CKD) program drug NP-251 (Repirinast), entitled "Compositions and Methods for Treating Non-Alcoholic Steatohepatitis."

Vancouver, BC, May 3, 2023--Algernon Pharmaceuticals Inc., a Canadian clinical stage pharmaceutical development company, announced tioday that its subsidiary Algernon NeuroScience (AGN Neuro), has completed dosing of the second cohort in its escalating dose Phase 1 clinical study of an intravenous formulation of AP-188 ("N,N-Dimethyltryptamine" or "DMT").

Vancouver, BC, March 8, 2023--Algernon Pharmaceuticals Inc., a clinical stage pharmaceutical development company, announced that its subsidiary Algernon NeuroScience (AGN Neuro) has appointed Dr. David L. Brody as a consultant for its clinical research program for the treatment of Traumatic Brain Injury (TBI) with AP-188 ("N,N-Dimethyltryptamine or DMT").

Vancouver, BC, March 2, 2023--Algernon Pharmaceuticals Inc., a clinical stage pharmaceutical development company, announced that its subsidiary Algernon NeuroScience (AGN Neuro) has added a new clinical research program for the treatment of Traumatic Brain Injury (TBI) with AP-188 ("N,N-Dimethyltryptamine or DMT").

Vancouver, BC, February 17, 2023--Algernon Pharmaceuticals Inc., a Canadian clinical stage pharmaceutical development company, announced that its subsidiary Algernon NeuroScience (AGN Neuro), has completed dosing of the first cohort in its Phase 1 clinical study of an intravenous formulation of AP-188 ("N,N-Dimethyltryptamine" or "DMT"), a known psychedelic compound that is part of the tryptamine family.

Vancouver, BC, January 19, 2023--Algernon Pharmaceuticals Inc., a Canadian clinical stage pharmaceutical development company, announced that its subsidiary, Algernon NeuroScience (AGN Neuro), has dosed the first subject in its Phase 1 clinical study of an intravenous formulation of AP-188 ("N,N-Dimethyltryptamine" or "DMT") in the Netherlands.

Vancouver, BC, January 10, 2023--Algernon Pharmaceuticals Inc., a Canadian clinical stage pharmaceutical development company, announced that it is planning a 180 patient, 90-day Phase 2b clinical study of NP-120 ("Ifenprodil") for chronic cough to begin in Q3 of 2023.

Vancouver, BC, January 5, 2023--Algernon Pharmaceuticals Inc., a clinical stage pharmaceutical development company, announced that it has established Algernon NeuroScience (AGN Neuro), a new wholly-owned private subsidiary of AGN Pharma, to advance the Company's psychedelic DMT stroke program.